BHCM
REGN icon

Brevan Howard Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brevan Howard Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
1,979
+1,645
+493% +$1.12M 0.01% 958
2026
Q1 		$258K Sell
334
-19,651
-98% -$15M ﹤0.01% 1726
2025
Q4 		$15.4M Buy
19,985
+14,745
+281% +$10M 0.17% 80
2025
Q3 		$2.95M Sell
5,240
-1,442
-22% -$815K 0.01% 412
2025
Q2 		$3.51M Sell
6,682
-657
-9% -$367K 0.02% 508
2025
Q1 		$4.65M Sell
7,339
-351
-5% -$241K 0.04% 145
2024
Q4 		$5.48M Buy
7,690
+4,506
+142% +$3.78M 0.04% 135
2024
Q3 		$3.35M Buy
+3,184
New +$3.54M 0.02% 174
2024
Q2 		– Sell
-3,106
Closed -$2.99M – 1347
2024
Q1 		$2.99M Buy
3,106
+1,943
+167% +$1.85M 0.03% 107
2023
Q4 		$1.02M Buy
+1,163
New +$958K 0.01% 229

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Brevan Howard Capital Management's REGN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 493% in Q2 2026, buying an estimated $1.12M and bringing the position to 1,979 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #958.

Brevan Howard Capital Management first reported a position in REGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $15.4M in Q4 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Brevan Howard Capital Management held 1,979 shares of Regeneron Pharmaceuticals worth $1.23M as of Q2 2026.
  • Brevan Howard Capital Management bought 1,645 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.12M.
  • Regeneron Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #958 holding.
  • Brevan Howard Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Brevan Howard Capital Management's Regeneron Pharmaceuticals position peaked at $15.4M in Q4 2025.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.